Biotech Values

[DewDiligence]

SNY’s unit f/k/a Genzyme Biosurgery acquires Pluromed for an undisclosed price:

http://finance.yahoo.com/news/sanofi-acquire-pluromed-inc-expanding-120000496.html

Sanofi will commercialize Pluromed's LeGoo, a highly innovative FDA approved and CE marked gel for temporary endovascular occlusion of blood vessels during surgical procedures… LeGoo is a thermo-sensitive biocompatible and non-toxic liquid gel that forms a plug when injected into a blood vessel to temporarily stop blood flow. The plug dissolves rapidly via cooling or spontaneously after several minutes. Once dissolved, the plug cannot reform because the concentration is too low. In a prospective, randomized study, LeGoo has been shown to provide better operating conditions than conventional occlusion techniques, by limiting blood flow into a surgical field without causing damage to the vessels. The study also showed a reduction in the time required to perform an anastomosis for beating heart surgery when using LeGoo. Time is critical to patient outcomes in these types of surgical interventions.